Overview
- The schizophrenia spectrum and other psychotic disorders are unified by the presence of one or more core psychotic domains: hallucinations, delusions, disorganised thinking (formal thought disorder), grossly disorganised or abnormal motor behaviour (including catatonia), and negative symptoms.
- DSM-5-TR groups these conditions under a single chapter heading, recognising that psychosis represents a dimensional clinical phenotype.
- ICD-11 similarly adopts a spectrum approach and no longer requires Schneiderian first-rank symptoms for a diagnosis of schizophrenia, a significant departure from ICD-10.
- Only disorders grouped under "Schizophrenia Spectrum and Other Psychotic Disorders" in DSM-5-TR are conventionally characterised by psychotic symptoms as the key defining clinical feature.
- However, psychosis also occurs as an associated feature across affective disorders, neurodevelopmental disorders, neurocognitive disorders, and some personality disorders (beyond schizotypal type).
Accurate differential diagnosis, prognosis, and treatment planning depend on systematically excluding substance/medication-induced psychotic disorder and psychotic disorder due to another medical condition before assigning a primary schizophrenia spectrum diagnosis.
DSM-5-TR Schizophrenia Spectrum: Full Disorder List
| Disorder |
|---|
| Schizophrenia |
| Schizophreniform disorder |
| Brief psychotic disorder |
| Schizoaffective disorder |
| Delusional disorder |
| Schizotypal personality disorder |
| Substance/medication-induced psychotic disorder |
| Psychotic disorder due to another medical condition |
| Catatonia associated with another mental disorder |
| Catatonic disorder due to another medical condition |
| Unspecified catatonia |
| Other specified schizophrenia spectrum and other psychotic disorder |
| Unspecified schizophrenia spectrum and other psychotic disorder |
Epidemiology
- Schizophrenia has a worldwide prevalence of approximately 0.5-1%.
- Life expectancy is reduced by approximately 15-20 years compared to the general population, attributable to suicide risk (lifetime risk approximately 5% in both schizophrenia and schizoaffective disorder, higher in those with depressive symptoms) and excess medical morbidity (cardiovascular, metabolic, respiratory illness).
Key epidemiological features:
- Higher incidence in migrant and refugee populations; elevated rates in urban versus rural settings
- Comorbid substance use disorder is the rule rather than the exception; cannabis use disorder is particularly prevalent
- First-episode psychosis (FEP) typically presents in late adolescence to early adulthood; males have earlier onset (late teens to mid-20s) than females (mid-20s to early 30s)
- The prevalence of schizophrenia has remained relatively stable over time despite fluctuations in substance use (including cannabis and hallucinogens)
Aetiology and Pathophysiology
Genetic Factors
- The lifetime risk in first-degree biological relatives is approximately 8-12 times higher than the general population rate.
- Monozygotic twin concordance is approximately 40-50%, confirming both substantial genetic loading and significant environmental contribution.
- Family studies demonstrate overlapping familial risk between schizophrenia, schizoaffective disorder, and bipolar disorder, challenging a strict Kraepelinian dichotomy.
- Copy number variants, notably the 22q11.2 deletion (velocardiofacial syndrome), confer markedly elevated psychosis risk (approximately 20-30% lifetime risk of schizophrenia spectrum disorder).
- The 22q11 phenotype includes elongated face, tubular nose with wide nasal bridge, small mouth, low facial tone, learning disabilities, and congenital malformations (cardiac, palatal).
- A polygenic architecture of many risk alleles of small individual effect interacts with environmental factors.
- Family studies confirm that increased psychosis risk in relatives of individuals with schizophrenia extends beyond schizophrenia alone to include schizoaffective disorder, bipolar I disorder, MDD with psychotic features, and substance-induced psychoses.
Neurodevelopmental Model
- Schizophrenia is conceptualised as a neurodevelopmental disorder with disrupted prefrontal cortical maturation, abnormal synaptic pruning, and dysconnectivity between cortical and subcortical networks.
- Premorbid schizoid or schizotypal personality features in childhood, quiet, passive, introverted, emotionally aloof, reclusive; few friendships; preference for solitary activities, are followed by a prodromal phase characterised by attenuated psychotic symptoms (magical thinking, ideas of reference, perceptual illusions, derealization/depersonalization), cognitive decline, and social withdrawal before the first frank psychotic episode.
Neurotransmitter Systems
| System | Proposed Mechanism | Clinical Relevance |
|---|---|---|
| Dopamine (D2) | Subcortical hyperdopaminergia → positive symptoms; prefrontal hypodopaminergia → negative/cognitive symptoms | D2 blockade is the primary mechanism of all antipsychotics |
| Glutamate (NMDA) | NMDA receptor hypofunction → disinhibition of mesolimbic dopamine; disrupted cortical synchrony; single NMDA antagonist dose can produce persisting hippocampal glutamatergic changes | NMDA antagonists (PCP, ketamine) model schizophrenia-like states; target for novel therapeutics |
| Serotonin (5-HT2A) | Cortical 5-HT2A antagonism by SGAs reduces EPS and may improve negative/cognitive symptoms; persistent serotonergic dysregulation may contribute to hallucinogen-induced persisting psychosis | Explains efficacy of atypical antipsychotics beyond pure D2 blockade |
| GABA | Reduced parvalbumin-positive interneuron function → cortical gamma oscillation deficits | Associated with cognitive and negative symptom dimensions |
Environmental Risk Factors
- Cannabis: meta-analyses show approximately 1.4-fold increased odds of psychotic symptoms with any cannabis use; approximately 2.1-fold with regular use; approximately 4-fold with high-potency (high-THC) cannabis. Early-onset use carries the greatest risk. Young people with psychosis who use cannabis have first-episode onset on average 2 years earlier than non-users. Persistent cannabis use after FEP worsens clinical outcomes; cessation improves trajectory.
- Obstetric complications, prenatal infections, maternal stress
- Urban birth and upbringing; migration and social adversity
- Childhood trauma and abuse
Clinical Features and DSM-5-TR Criteria
Schizophrenia
| Criterion | Requirement |
|---|---|
| A, Characteristic symptoms | ≥2 of: delusions, hallucinations, disorganised speech, grossly disorganised or catatonic behaviour, negative symptoms; at least one must be delusions, hallucinations, or disorganised speech |
| B, Functional decline | Significant decline in work, interpersonal relations, or self-care since onset |
| C, Duration | Continuous signs of disturbance for ≥6 months (including ≥1 month of active Criterion A symptoms, or less if treated) |
| D, Schizoaffective/mood disorder exclusion | Schizoaffective disorder and mood disorder with psychotic features ruled out |
| E, Substance/medical exclusion | Not attributable to substances, medications, or another medical condition |
| F, ASD exclusion | If ASD history present, schizophrenia requires prominent hallucinations/delusions for ≥1 month |
- DSM-5 changes from DSM-IV: removed special status for "bizarre" delusions and Schneiderian first-rank hallucinations (previously allowing single-symptom Criterion A satisfaction); removed subtypes (paranoid, disorganised, catatonic, undifferentiated, residual); rewording of negative symptoms ("affective flattening" → "restricted affect"; "alogia or avolition" → "avolition/asociality").
- ICD-11 similarly removed first-rank symptom privilege.
- Auditory hallucinations are the most common hallucinatory modality in schizophrenia.
- In its most severe form, schizophrenia presents with bizarre delusions and hallucinations producing prominent behavioural and functional changes.
Negative Symptoms
Negative symptoms (avolition, asociality, alogia, anhedonia, blunted/restricted affect) are a major contributor to functional disability and are often refractory to treatment. They may be:
- Primary: intrinsic to the illness
- Secondary: to positive symptoms, depression, medication side effects (particularly D2 blockade causing emotional blunting), or social deprivation
Negative symptoms are relatively uncommon as a predominant feature of schizophreniform disorder and represent a poor prognostic feature when present.
Spectrum Conditions: Comparative Summary
| Disorder | Key Features | Duration Criterion |
|---|---|---|
| Brief psychotic disorder | ≥1 Criterion A symptom (excluding negative symptoms alone); may include emotional turmoil/perplexity | 1 day to <1 month; full return to premorbid function |
| Schizophreniform disorder | Full Criterion A met; return to baseline by definition within 6 months; emotional turmoil/perplexity may indicate good prognosis; negative symptoms are poor prognostic features | >1 month and <6 months |
| Schizophrenia | Full DSM-5-TR criteria including functional decline | ≥6 months continuous disturbance |
| Schizoaffective disorder | Criterion A + concurrent major mood episode (depressive or manic); psychosis for ≥2 weeks independent of mood episode; prevalence approximately one-third that of schizophrenia | Variable; episodic |
| Delusional disorder | ≥1 delusion(s) ≥1 month; no other Criterion A symptoms; functioning relatively preserved | ≥1 month |
| Schizotypal personality disorder | Pervasive social/interpersonal deficits, cognitive/perceptual distortions, eccentricities; classified within the schizophrenia spectrum in DSM-5-TR | Lifelong trait pattern |
Catatonia
- Catatonia may occur in the context of schizophrenia spectrum disorders, mood disorders, and medical conditions (encephalitis, head trauma, hepatic encephalopathy, neoplasms).
- Acute presentation often includes stupor.
- DSM-5-TR specifies catatonia as a specifier for multiple disorders as well as standalone diagnoses (catatonia associated with another mental disorder; catatonic disorder due to another medical condition; unspecified catatonia).
Substance/Medication-Induced Psychotic Disorder
Key diagnostic features (DSM-5-TR):
- Prominent hallucinations and/or delusions
- Develop during or soon after substance intoxication or withdrawal, or following exposure to a medication
- Symptoms expected to resolve within 1 month of substance discontinuation (in clinical practice, most cases in youth resolve within 7-10 days)
- Not better explained by a primary psychotic disorder, evidence for this includes symptoms predating substance use or persisting during sustained abstinence
- Does not occur exclusively during delirium (if so, diagnose delirium)
- Negative symptoms are less common in substance-induced psychosis than in primary schizophrenia spectrum disorders; functional decline occurs in both
- Distinguishing from schizophreniform disorder: rapid onset in the context of significant substance use history raises suspicion for substance-induced psychosis; longitudinal assessment is often essential.
- Substance-induced psychosis may be episodic with return to full baseline.
Conversion to primary psychotic disorder: A 2018 longitudinal study (n = 6,788 substance-induced psychoses, followed up to 20 years) found:
- 28% of hallucinogen-induced psychosis cases eventually converted to schizophrenia or bipolar disorder
- Marijuana-, amphetamine-, and alcohol-induced psychoses carried higher conversion risk to schizophrenia than hallucinogen-induced psychosis
- Sedative-, marijuana-, and alcohol-induced psychoses had higher conversion rates to bipolar disorder than hallucinogen-induced psychosis
- Age 16-25 at time of substance-induced psychosis and self-harm after the episode were associated with higher conversion risk to either diagnosis
- A 2019 longitudinal study (n = 7,606) found familial risk scores for nonaffective psychosis predicted progression from substance-induced psychosis to schizophrenia, supporting a drug-precipitated disorder model in highly vulnerable individuals
Hallucinogens specifically:
- Hallucinogen-induced psychosis diagnosis requires symptoms significantly exceeding expected intoxication duration/intensity; if occurring solely during delirium, diagnose hallucinogen intoxication delirium
- PCP-induced psychosis may persist up to 6 weeks but typically resolves completely; benzodiazepines used for agitation; antipsychotics used (limited evidence)
- If symptoms persist beyond 4-8 weeks, consider underlying primary psychotic disorder precipitated or unmasked by hallucinogen use
- Classical hallucinogens appear not to produce de novo chronic psychosis in individuals without psychotic diathesis; population-level studies show no significant association between psychedelic use and increased rates of psychosis; schizophrenia prevalence has remained stable despite fluctuating hallucinogen use
- Hallucinogen Persisting Perception Disorder (HPPD): perceptual disturbances after hallucinogen use with intact reality testing; if reality testing is lost, consider psychotic disorder; common comorbidities include panic disorder, alcohol use disorder, MDD, bipolar I disorder, and schizophrenia spectrum disorders
- Cannabis-induced psychotic disorder has a robust evidence base; cannabis carries elevated risk compared to other substances
Ongoing monitoring: Even when symptoms fully resolve after substance-induced psychosis, periodic monitoring for psychotic symptoms is strongly recommended, particularly for younger patients, given that a substantial minority will eventually receive a formal psychotic disorder diagnosis.
Assessment
Clinical Approach
Assessment requires longitudinal evaluation combining clinical interview, collateral history (family, carers, GP), physical examination, and targeted investigations. Key assessment domains:
- Psychiatric history and mental state examination
- Premorbid functioning and prodromal course
- Substance use history and toxicology screening (essential for all new-onset psychosis)
- Medication history including OTC medications and herbal products (may produce acute psychosis)
- Medical and neurological history
- Risk assessment (suicide, self-harm, aggression, vulnerability)
- Functional capacity and social circumstances
Investigations
| Investigation | Indication |
|---|---|
| FBC, UEC, LFTs, TFTs, fasting glucose and lipids, prolactin, vitamin B12/folate | Routine first-episode workup; antipsychotic baseline |
| Urine drug screen (UDS) | All new-onset psychosis presentations |
| MRI brain | First-episode psychosis to exclude organic cause |
| EEG | Suspected seizure disorder |
| Anti-NMDAR and other autoimmune encephalitis antibodies (serum/CSF) | Clinically indicated; encephalitis presenting as psychosis |
| Toxicological screen and medication review | Substance-induced and medication-induced psychosis |
Validated Rating Scales
| Scale | Domains | Clinical Use |
|---|---|---|
| PANSS (Positive and Negative Syndrome Scale) | Positive (7), Negative (7), General Psychopathology (16) | Severity; research and clinical trials |
| BPRS (Brief Psychiatric Rating Scale) | 18 items: psychosis, mood, anxiety | Treatment response monitoring |
| SANS/SAPS | Negative (SANS) and positive (SAPS) symptom severity | Research; detailed negative symptom characterisation |
| CDSS (Calgary Depression Scale for Schizophrenia) | 9-item; depression distinct from negative symptoms | Differentiate depression from negative symptoms |
| GAF (Global Assessment of Functioning) | Overall psychosocial functioning | Functional outcome monitoring |
Differential Diagnosis
| Condition | Key Distinguishing Features |
|---|---|
| Substance/medication-induced psychotic disorder | Symptoms emerge during or shortly after intoxication/withdrawal; resolve within 1 month of cessation; no psychotic history during sustained abstinence; negative symptoms less prominent |
| Psychotic disorder due to another medical condition | Identified medical condition (autoimmune encephalitis, epilepsy, CNS neoplasm, SLE, thyroid disorder, hepatic encephalopathy, head trauma) causally related temporally |
| Bipolar disorder with psychotic features | Psychosis only during mood episodes; prominent manic or depressive syndrome; episodic with full interepisode recovery |
| MDD with psychotic features | Psychosis confined to depressive episodes; mood-congruent content typical |
| Schizoaffective disorder | Criterion A symptoms for ≥2 weeks independent of mood episode |
| Delusional disorder | Non-bizarre delusions only; no prominent hallucinations, formal thought disorder, or marked functional impairment beyond the delusion |
| Autism spectrum disorder | Developmental onset before age 3 years; core social communication deficits; psychosis may be comorbid but requires separate documentation; genetic overlap with schizophrenia |
| Cluster A personality disorders | Schizotypal or paranoid features without frank psychotic episodes; lifelong pattern |
| Delirium | Fluctuating consciousness; identifiable organic cause; hallucinations often visual; psychosis occurs exclusively in delirium context, substance-induced or hallucinogen intoxication delirium diagnosed instead |
| HPPD | Perceptual disturbances post-hallucinogen use; reality testing intact; neuroimaging typically negative |
Management
Pharmacological
Antipsychotic Medications
- All antipsychotics share dopamine D2 receptor antagonism as their primary mechanism.
- SGAs additionally block 5-HT2A receptors with variable affinity for histaminergic, muscarinic, and alpha-adrenergic receptors.
| Medication | Key Side Effects | Special Monitoring |
|---|---|---|
| Olanzapine | Weight gain, metabolic syndrome, sedation, hyperglycaemia, postural hypotension | Fasting glucose, lipids, weight, BP |
| Risperidone | EPS, hyperprolactinaemia, hyperglycaemia, hypotension | Prolactin, EPS, metabolic |
| Quetiapine | Sedation, metabolic effects, NMS, hyperglycaemia, headache | Fasting glucose, lipids, ophthalmology (lens, cataract risk) |
| Aripiprazole | Akathisia, insomnia, NMS, hyperglycaemia, seizures, hypotension | Metabolic (lower impact), akathisia rating |
| Paliperidone | EPS, hyperprolactinaemia, hyperglycaemia | As risperidone |
| Ziprasidone | Sedation, EPS, hyperglycaemia, hypotension | QTc prolongation (black box: risk of sudden death) |
| Asenapine | EPS, NMS, dyslipidaemia, blood dyscrasias, QTc prolongation, orthostatic hypotension, hyperglycaemia; increased mortality in dementia | Metabolic, ECG, blood counts |
| Amisulpride | Hyperprolactinaemia, QTc prolongation, EPS at high doses | ECG, prolactin |
| Clozapine | Agranulocytosis (black box), seizures (black box), myocarditis (black box), metabolic syndrome, sialorrhoea, sedation, tachycardia, hypotension, weight gain, hyperthermia | Mandatory WBC/ANC monitoring per TGA protocol; ECG, troponin, lipids |
| Iloperidone | Metabolic effects | Metabolic monitoring |
- Clozapine is indicated for treatment-resistant schizophrenia (inadequate response to ≥2 antipsychotics at adequate dose and duration) and for reduction of recurrent suicidal behaviour in schizophrenia/schizoaffective disorder.
- Mandatory haematological monitoring is required under TGA-mandated protocols.
Long-acting injectable (LAI) antipsychotics improve adherence and reduce relapse; Australian formulations include paliperidone palmitate (monthly, 3-monthly), risperidone microspheres, olanzapine pamoate (post-injection monitoring required), and aripiprazole monohydrate.
- Hallucinogen-induced and PCP-induced psychosis: antipsychotics are used (limited evidence for PCP); benzodiazepines control agitation; treatment aims to prevent irreversible consequences and preserve relationships and functional capacity.
- Chronic psychosis with onset during substance use is treated as first-break psychosis with particular attention to minimising future substance-related harms.
Adjunctive Pharmacotherapy
- Benzodiazepines: short-term management of agitation; avoid long-term use
- Mood stabilisers (valproate, lithium): adjunctive in schizoaffective disorder or persistent aggression/impulsivity
- Antidepressants: comorbid depressive disorder in schizophrenia, particularly after positive symptom stabilisation
Psychological Interventions
| Intervention | Evidence Base | Target |
|---|---|---|
| CBT for Psychosis (CBTp) | Strong RCT evidence; RANZCP and NICE recommended | Positive symptom distress, insight, depression, risk |
| Family Psychoeducation/Family Therapy | Reduces relapse; improves expressed emotion | Carer burden, relapse prevention |
| Cognitive Remediation Therapy (CRT) | Moderate evidence; best combined with vocational rehabilitation | Cognitive deficits |
| Social Skills Training | Functional outcomes | Social and occupational functioning |
| Supported Employment (IPS model) | Strong evidence for vocational outcomes | Return to work/education |
| Early Psychosis Intervention (EPPIC model, headspace) | Reduces DUP; improves long-term outcomes | First-episode psychosis |
Social and Community Interventions
- Assertive community treatment (ACT): reduces hospitalisation for complex, high-support needs
- Housing First: stable housing as a determinant of recovery
- Peer support: lived-experience workers in community mental health teams
- Carer support: psychoeducation, respite, carer-specific services
- NDIS (Australia): psychosocial disability supports; psychiatrists contribute to capacity and support documentation
- Multidisciplinary community mental health teams: coordinated care model
Prognosis
Key prognostic factors:
| Good Prognosis | Poor Prognosis |
|---|---|
| Acute onset | Insidious onset |
| Short DUP | Long DUP |
| Prominent affective features / emotional turmoil at onset | Prominent negative symptoms |
| Good premorbid functioning | Poor premorbid functioning |
| Female sex | Male sex, younger age of onset |
| Absence of substance use | Comorbid substance use disorder |
| Good treatment response and adherence | Treatment resistance |
| Strong social support | Social isolation |
- Persistent cannabis use after FEP is associated with significantly worse outcomes; cessation improves clinical trajectory.
- Young people with psychosis who use cannabis have first-episode onset approximately 2 years earlier than non-users.
Conversion rates from substance-induced psychosis to primary psychotic disorder vary by substance: marijuana-, amphetamine-, and alcohol-induced psychoses carry higher conversion risk to schizophrenia than hallucinogen-induced psychosis.
$$\text{Reducing DUP} \Rightarrow \text{improved functional outcome (supported by multiple meta-analyses)}$$
Special Populations
Pregnancy and Perinatal Period
- Relapse risk during pregnancy and postpartum is high if antipsychotics are ceased.
- All antipsychotics cross the placenta; neonatal EPS and withdrawal syndromes are documented.
- Metabolic risks of olanzapine and clozapine are relevant in the context of gestational diabetes.
- RANZCP perinatal mental health guidelines support continuation of effective antipsychotic treatment with close obstetric co-management.
Older Adults
- Late-onset schizophrenia (onset after 40 years) and very late-onset schizophrenia-like psychosis (onset after 60 years) require thorough medical investigation given higher prevalence of organic causes.
- Antipsychotic doses are generally lower.
- Tardive dyskinesia risk increases with age and cumulative antipsychotic exposure.
Children and Adolescents
Early-onset schizophrenia (EOS, onset before 18